Metoprolol Pharmaclan

Metoprolol Tartrate, the active ingredient in Metoprolol Pharmaclan, is a beta‑adrenergic receptor blocker presented as a tablet formulation for oral use. It treats hypertension, angina pectoris, post‑myocardial infarction, chronic heart failure and cardiac arrhythmias in adult patients.

GNH USA supplies Metoprolol Pharmaclan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoprolol Pharmaclan is a beta‑blocker used in several cardiovascular conditions.

- Hypertension: lowers blood pressure by reducing cardiac output and renin release. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. - Post‑myocardial infarction: improves survival by limiting arrhythmias and remodeling. - Chronic heart failure: reduces mortality and hospitalisation through heart‑rate control. - Cardiac arrhythmias: stabilises rhythm by slowing conduction through the AV node.

Metoprolol Pharmaclan may cause a range of adverse reactions.

Common Side Effects: - Fatigue or tiredness. - Dizziness or light‑headedness. - Bradycardia (slow heart rate). - Cold extremities. - Headache. - Mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe bradycardia or heart block. - Marked hypotension. - Bronchospasm, especially in patients with asthma or COPD. - Allergic reactions such as rash or angioedema. - Depression or mood changes. - Worsening heart failure.

Before initiating Metoprolol Pharmaclan, consider the following safety measures.

- Monitor blood pressure: check regularly during dose titration. - Assess heart rate: avoid use in patients with resting bradycardia. - Caution in asthma/COPD: may exacerbate bronchospasm. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Metoprolol Pharmaclan can interact with several drug classes.

Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia. - Calcium‑channel blockers (verapamil, diltiazem): risk of severe AV block. - Clonidine: abrupt withdrawal may cause rebound hypertension.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may enhance hypotensive effect. - Diuretics: increase risk of electrolyte imbalance. - Antidiabetic agents: may mask hypoglycaemia symptoms. - Antidepressants (SSRIs): possible increase in plasma metoprolol levels.